Umlaut.bio GmbH

Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules under development inhibit key steps in tRNA modification thereby preventing overactivation of a multitude of signalling transduction pathways. This is a hallmark of uncontrolled cancer growth as well as autoimmune diseases which can not be addressed with chemotherapy or targeting individual proteins.